Suppliers and packagers for LAMIVUDINE

LAMIVUDINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	LAMIVUDINE	lamivudine	SOLUTION;ORAL	077695	ANDA	Rising Pharma Holdings, Inc.	57237-274-24	240 mL in 1 BOTTLE (57237-274-24)	2016-11-21
Aurobindo Pharma	LAMIVUDINE	lamivudine	SOLUTION;ORAL	077695	ANDA	Aurobindo Pharma Limited	65862-055-24	240 mL in 1 BOTTLE (65862-055-24)	2016-11-21
Chartwell Molecular	LAMIVUDINE	lamivudine	SOLUTION;ORAL	203564	ANDA	Chartwell RX, LLC	62135-706-24	2 TRAY in 1 BOX (62135-706-24) / 10 CUP in 1 TRAY / 30 mL in 1 CUP (62135-706-30)	2014-10-31
Chartwell Molecular	LAMIVUDINE	lamivudine	SOLUTION;ORAL	203564	ANDA	Chartwell RX, LLC	62135-706-37	240 mL in 1 BOTTLE, PLASTIC (62135-706-37)	2014-10-31
Chartwell Molecular	LAMIVUDINE	lamivudine	SOLUTION;ORAL	203564	ANDA	Chartwell Govermental & Specialty RX, LLC.	68999-706-24	2 TRAY in 1 BOX (68999-706-24) / 10 CUP in 1 TRAY / 30 mL in 1 CUP (68999-706-30)	2014-10-31
Annora	LAMIVUDINE	lamivudine	TABLET;ORAL	211306	ANDA	Camber Pharmaceuticals, Inc.	31722-001-02	20 BLISTER PACK in 1 CARTON (31722-001-02) / 10 TABLET, FILM COATED in 1 BLISTER PACK	2019-03-21
Annora	LAMIVUDINE	lamivudine	TABLET;ORAL	211306	ANDA	Camber Pharmaceuticals, Inc.	31722-001-60	60 TABLET, FILM COATED in 1 BOTTLE (31722-001-60)	2019-03-21

Lamivudine Supply Chain Analysis

Last updated: February 19, 2026

This report identifies key suppliers of lamivudine, a nucleoside analog reverse transcriptase inhibitor. The analysis focuses on manufacturers of the active pharmaceutical ingredient (API) and critical intermediates, their production capacities, regulatory compliance, and potential market impact.

Who are the Primary Lamivudine API Manufacturers?

Major manufacturers of lamivudine API include companies with established chemical synthesis capabilities and significant market presence in antiviral drugs. These suppliers operate globally, with a concentration in Asia.

• Shandong Xinhua Pharmaceutical Co., Ltd. (China): A significant producer with a long history in API manufacturing. Xinhua is a vertically integrated company, often controlling multiple steps of the synthesis process. Their facilities are typically GMP-certified by various international regulatory bodies.
• Gland Pharma Ltd. (India): Known for its strong focus on generic injectables and oral solids, Gland Pharma also produces APIs. They have multiple manufacturing sites compliant with US FDA and European regulatory standards.
• Dr. Reddy's Laboratories (India): A large Indian pharmaceutical company with a broad API portfolio. Dr. Reddy's has robust R&D and manufacturing infrastructure, capable of producing complex APIs.
• Hetero Drugs Ltd. (India): One of the largest API manufacturers in India, Hetero has extensive production capacity and a wide range of therapeutic areas. Their operations are compliant with international GMP standards.
• Lupin Limited (India): A global pharmaceutical company with significant API manufacturing operations. Lupin focuses on quality and regulatory adherence, supplying to regulated markets.

These companies compete based on price, quality, regulatory compliance, and scale of production. Their ability to meet stringent pharmacopoeial standards (USP, EP, JP) and maintain consistent supply is crucial for drug formulation companies.

What are the Key Intermediates for Lamivudine Synthesis?

The synthesis of lamivudine involves several key intermediates. The reliable supply of these precursors is critical for API manufacturers. Common intermediates include:

• 2'-deoxy-5-fluorocytidine: A critical nucleoside precursor.
• 1,3-dioxolane: Used in the synthesis to create the dioxolane ring structure.
• Various protected sugar derivatives: These are essential for controlling stereochemistry and reactivity during synthesis.

Suppliers of these intermediates are often specialized chemical manufacturers. For example, companies like Sigma-Aldrich (Merck KGaA) and TCI (Tokyo Chemical Industry Co., Ltd.) offer a range of high-purity reagents and intermediates for pharmaceutical synthesis. However, for large-scale commercial production, dedicated intermediate suppliers who can provide multi-ton quantities at competitive prices are more relevant. These might include:

• Chinese chemical manufacturers: Numerous companies in China specialize in custom synthesis and bulk production of pharmaceutical intermediates. Specific company names often shift due to market dynamics and confidentiality agreements.
• Indian specialty chemical companies: India also has a strong base of companies producing advanced intermediates for the pharmaceutical sector.

The quality and consistency of these intermediates directly impact the final API yield and purity. Manufacturers often audit their intermediate suppliers rigorously to ensure compliance and quality control.

What are the Regulatory and Quality Considerations for Lamivudine Production?

The production of lamivudine API and its intermediates is subject to strict regulatory oversight. Key considerations include:

• Good Manufacturing Practices (GMP): Compliance with current Good Manufacturing Practices (cGMP) as defined by regulatory agencies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO) is mandatory. This ensures product quality, safety, and efficacy.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facility, and quality control of the API. Formulators reference these DMFs in their drug product applications.
• Impurity Profiling: Identification, quantification, and control of impurities are critical. Regulatory guidelines, such as ICH Q3A and Q3B, set limits for impurities. Manufacturers must demonstrate robust analytical methods for impurity detection and control.
• Stability Studies: Comprehensive stability data demonstrating the API's shelf-life under various storage conditions is required.
• Site Inspections: Manufacturing facilities are subject to regular inspections by regulatory authorities to verify ongoing GMP compliance.

Suppliers must demonstrate adherence to these standards to be considered by pharmaceutical companies seeking to formulate lamivudine-based drugs. Companies with a strong regulatory track record and successful inspection history are preferred.

What is the Current Market Landscape for Lamivudine Supply?

The lamivudine market is characterized by a mature generic drug landscape, primarily driven by its use in combination therapies for HIV and Hepatitis B.

• Dominance of Generic Manufacturers: The patent protection for lamivudine has long expired, leading to a highly competitive generic market. This intensifies price pressure on API manufacturers.
• Geographic Concentration: API production is heavily concentrated in India and China, leveraging lower manufacturing costs and established chemical synthesis expertise.
• Demand Drivers:
  • HIV Treatment: Lamivudine remains a cornerstone of many first-line and second-line HIV treatment regimens, often in fixed-dose combinations (e.g., Abacavir/Lamivudine, Tenofovir/Lamivudine).
  • Hepatitis B Treatment: It is also widely used for chronic Hepatitis B infection.
  • Emerging Markets: Growing access to antiretroviral therapy in developing countries continues to drive demand.
• Supply Chain Vulnerabilities: While competitive, the reliance on a few key producing regions can create supply chain vulnerabilities. Geopolitical events, trade disputes, or unexpected regulatory changes in major producing countries can impact global availability and pricing.
• Quality and Cost Trade-offs: Drug formulators face a constant balance between securing low-cost API and ensuring high-quality, compliant material. Companies that can consistently deliver both are well-positioned.

The market for lamivudine API is stable but highly price-sensitive. Innovation in this segment typically focuses on process optimization for cost reduction and environmental sustainability rather than novel synthesis routes.

Who are the Key Formulators Using Lamivudine API?

Numerous pharmaceutical companies globally formulate lamivudine into finished drug products. These companies purchase API from manufacturers and combine it with excipients to create tablets, capsules, or oral solutions. Key formulators include:

• Major Generic Pharmaceutical Companies:
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Viatris Inc. (USA) (formed from the merger of Mylan and Upjohn)
  • Aurobindo Pharma Ltd. (India)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Cipla Ltd. (India)
• Companies Specializing in Antivirals: Many companies, particularly those with a focus on HIV and Hepatitis B, will be significant purchasers of lamivudine API. Examples include companies that market combination therapies.
• Global Health Organizations and Procurement Agencies: Organizations like the Global Fund to Fight AIDS, Tuberculosis and Malaria, and national procurement agencies often contract with formulators for large volumes of antiretroviral drugs, thereby influencing API demand.

The choice of API supplier by these formulators is influenced by API price, consistent quality, regulatory documentation (DMFs), supply reliability, and payment terms. Long-term contracts are common to ensure stable supply chains.

What are the Patent Expirations and Generic Competition Implications?

Lamivudine's primary patents have expired globally, paving the way for extensive generic competition.

• Original Patents: The foundational patents for lamivudine expired decades ago in major markets. For instance, U.S. Patent 4,957,924 expired in 2007. Similar expirations occurred in Europe and other regions around the same timeframe.
• Formulation Patents: While API patents have expired, there can still be secondary patents related to specific formulations, manufacturing processes, or combination products that might offer some limited protection. However, these are generally less impactful than core compound patents.
• Impact on API Suppliers: The expiration of compound patents led to the entry of numerous generic API manufacturers, primarily from India and China. This has driven down API prices significantly.
• Competition for Formulators: Generic drug formulators can now produce and market lamivudine-containing products with reduced R&D and regulatory hurdles compared to originator products. This has increased affordability and accessibility of treatment worldwide.
• Market Saturation: The lamivudine API market is mature and highly competitive. API suppliers must focus on cost efficiency, high volume, and stringent quality control to maintain market share. Price is a primary differentiator.

The generic landscape ensures that lamivudine remains a cost-effective component in HIV and Hepatitis B treatment regimens.

Key Takeaways

• API Manufacturing Concentration: Lamivudine API production is dominated by a few large manufacturers, predominantly in India and China, including Shandong Xinhua Pharmaceutical, Gland Pharma, Dr. Reddy's Laboratories, Hetero Drugs, and Lupin Limited.
• Intermediate Sourcing: Reliable supply of key intermediates like 2'-deoxy-5-fluorocytidine is crucial, with specialized chemical manufacturers in Asia being primary sources.
• Regulatory Imperative: Strict adherence to GMP and detailed DMF filings are non-negotiable for API suppliers and intermediate providers.
• Mature Generic Market: Lamivudine is a well-established generic drug with expired primary patents, leading to intense price competition and high volume demand from global formulators.
• Formulator Base: Major generic pharmaceutical companies, including Teva, Viatris, Aurobindo, Sun Pharma, and Cipla, are significant purchasers of lamivudine API.

FAQs

1. What is the typical lead time for ordering bulk lamivudine API from major suppliers? Lead times can vary from 4 to 12 weeks, depending on the supplier's current production schedule, order volume, and existing inventory. Custom synthesis for specific purity requirements may extend this period.

2. Are there any known supply chain risks specific to lamivudine API production? Key risks include reliance on a limited number of manufacturing regions (India, China) for both API and intermediates, potential regulatory changes impacting production facilities, and disruptions due to geopolitical events or global health crises affecting shipping and raw material availability.

3. What are the most common pharmacopoeial standards for lamivudine API? The most common standards are those set by the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). Suppliers typically ensure their API meets at least one, and often multiple, of these compendial standards.

4. How does the cost of lamivudine API typically compare to other antiretroviral APIs? Lamivudine API is generally among the more cost-effective antiretroviral APIs due to its long history, mature manufacturing processes, and high volume generic production. Its cost is significantly lower than newer, patented antiretroviral agents.

5. Can pharmaceutical companies source lamivudine intermediates from multiple suppliers to mitigate risk? Yes, larger pharmaceutical companies often qualify and maintain relationships with multiple qualified intermediate suppliers to ensure continuity of supply and leverage competitive pricing, especially for critical, high-volume intermediates.

Citations

[1] U.S. Food and Drug Administration. (n.d.). U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/

[2] European Medicines Agency. (n.d.). European Medicines Agency. Retrieved from https://www.ema.europa.eu/en

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Tripartite Guideline - Impurities in New Drug Substances Q3A(R2). Retrieved from https://www.ich.org/

[4] United States Patent and Trademark Office. (n.d.). USPTO. Retrieved from https://www.uspto.gov/

[5] World Health Organization. (n.d.). World Health Organization. Retrieved from https://www.who.int/